Auvi-Q, an auto-injector epinephrine product now produced by Kaleo Pharmaceuticals (formerly produced by Sanofi) will be placed on the market sometime in 2017. They have yet to set a price, but most people believe they will only be a few dollars cheaper than the EpiPen (Arstechnica). It had previously been on the market but was taken off in 2015 over fears that the dosage was not correct in some units. Due to patent laws, a generic has yet to be developed, tested and sold until the patent expires in 2025 (NPR). It is not uncommon to see that drug prices elsewhere in the world are cheaper than the U.S. for various reasons. Some suggest Obamacare has driven those prices up as well, but I don’t believe it is Obamacare alone that causes a 247% increase since 2013. A similar version of the EpiPen is sold in France by another company for about $170 for a two-pack
Auvi-Q, an auto-injector epinephrine product now produced by Kaleo Pharmaceuticals (formerly produced by Sanofi) will be placed on the market sometime in 2017. They have yet to set a price, but most people believe they will only be a few dollars cheaper than the EpiPen (Arstechnica). It had previously been on the market but was taken off in 2015 over fears that the dosage was not correct in some units. Due to patent laws, a generic has yet to be developed, tested and sold until the patent expires in 2025 (NPR). It is not uncommon to see that drug prices elsewhere in the world are cheaper than the U.S. for various reasons. Some suggest Obamacare has driven those prices up as well, but I don’t believe it is Obamacare alone that causes a 247% increase since 2013. A similar version of the EpiPen is sold in France by another company for about $170 for a two-pack